MAP2K7 and Hodgkins lymphoma: found that the combination of Givinostat (a histone deacetylase inhibitor) and Sorafenib (an RAF/MEK/ERK inhibitor) promoted the production of ROS continuously and activated necroptotic cell death in Hodgkin’s lymphoma (HL) (21).